Loading company
Citius Pharmaceuticals, Inc.
CTXR · Nasdaq · ·
$0.56+0.3%Sep 29 close
- 1M
- -7.6%
- 6M
- -18.3%
- 1Y
- -55.1%
- 5Y
- -99.0%
CTXR · Nasdaq · ·
$0.56+0.3%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toSep 30, 2021 | Change |
|---|---|---|---|
| Total Revenue | $1.5M | $0.00 | — |
| Profit | -$11.9M | -$9.2M | -29.50% |
| Profit per share | -$0.34 | -$0.80 | +57.50% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Citius Pharmaceuticals, Inc. has no earnings call transcript available.
“The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR’s differentiated clinical profile,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok ® , a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Citius Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.